Publications Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma Published on December 1st, 2021 Authors: Matthias M Schneider, Marc Emmenegger, Catherine K Xu, Itzel Condado Morales, Georg Meisl, Priscilla Turelli, Chryssa Zografou, Manuela R Zimmermann, Beat M Frey, Sebastian Fiedler, Viola Denninger, Raphaël PB Jacquat, Lidia Madrigal, Alison Ilsley, Vasilis Kosmoliaptsis, Heike Fiegler, Didier Trono, Tuomas PJ Knowles, Adriano Aguzzi Life Science Alliance Nov 2021, 5 (2) e202101270; DOI: 10.26508/lsa.202101270 Abstract The clinical outcome of SARS-CoV-2 infections, which can range from asymptomatic to lethal, is crucially shaped by the concentration of antiviral antibodies and by their affinity to their targets. However, the affinity of polyclonal antibody responses in plasma is difficult to measure. Here Schneider and co-workers used microfluidic antibody affinity profiling (MAAP) to determine the aggregate affinities and concentrations of anti–SARS-CoV-2 antibodies in plasma samples of 42 seropositive individuals, 19 of which were healthy donors, 20 displayed mild symptoms, and 3 were critically ill. They found that dissociation constants, Kd, of anti–receptor-binding domain antibodies spanned 2.5 orders of magnitude from sub-nanomolar to 43 nM. Using MAAP they found that antibodies of seropositive individuals induced the dissociation of pre-formed spike-ACE2 receptor complexes, which indicates that MAAP can be adapted as a complementary receptor competition assay. By comparison with cytopathic effect–based neutralisation assays, they show that MAAP can reliably predict the cellular neutralisation ability of sera, which may be an important consideration when selecting the most effective samples for therapeutic plasmapheresis and tracking the success of vaccinations. Read the publication Instrument: Fluidity One-W Therapeutic area: Covid-19 A full list of recent publications in which our technology has been applied can be accessed here.